Innate Pharma S.A. (ETR:IDD)
Germany · Delayed Price · Currency is EUR | Market Cap | 149.15M -9.0% |
| Revenue (ttm) | 9.01M -55.2% |
| Net Income | -49.18M |
| EPS | -0.55 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 14.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1.600 |
| Previous Close | 1.650 |
| Day's Range | 1.600 - 1.600 |
| 52-Week Range | 1.086 - 2.100 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 17, 2026 |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking ant... [Read more]
Financial Performance
In 2025, Innate Pharma's revenue was 9.01 million, a decrease of -55.25% compared to the previous year's 20.12 million. Losses were -49.18 million, -0.59% less than in 2024.
Financial StatementsNews
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a confer...
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing i...
Innate Pharma price target raised to $9 from $8 at BTIG
BTIG analyst Jeet Mukherjee raised the firm’s price target on Innate Pharma (IPHA) to $9 from $8 and keeps a Buy rating on the shares. The firm notes that the…
Innate Pharma SA To Hold Conference Call Transcript
Innate Pharma SA To Hold Conference Call Transcript
Innate Pharma Secures €30M, Extends Cash Runway Into 2028
Innate Pharma NASDAQ: IPHA said it has raised €30 million in equity financing, providing funding to advance its strategic priorities, including the development of its lacutamab and IPH4502 programs an...
Innate Pharma Transcript: Investor update
A €30 million equity raise and a strategic partnership with Sobi extend the cash runway through Q1 2028, enabling continued advancement of key programs including lacutamab, IPH4502, and the ADC portfolio. Key clinical data for IPH4502 and monalizumab are expected later this year.
Innate Pharma Press release: Investor update
Innate Pharma issued a press release on August 14, 2026, disclosing material business information to investors.
Innate Pharma Slides: Investor update
Innate Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 14, 2026.
Innate Pharma Announces Conference Call and Webcast
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast.
Innate Pharma Slides: Company presentation
Innate Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 14, 2026.
Leerink upgrades Innate Pharma to Outperform after lacutamab deal
As previously reported, Leerink upgraded Innate Pharma (IPHA) to Outperform from Market Perform with a price target of $4, up from $3, citing enthusiasm for the company’s wholly-owned IPH4502. The…
Innate Pharma upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Innate Pharma (IPHA) to Outperform from Market Perform with a price target of $4, up from $3.
Innate Pharma price target raised to $7 from $5 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Innate Pharma (IPHA) to $7 from $5 and keeps a Buy rating on the shares. Innate Pharma’s lacutamab partnership…
Innate Pharma, Sobi to enable initiation of the TELLOMAK-3 study
Sobi and Innate Pharma (IPHA) announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma, a key…
Innate Pharma CMO Sonia Quaratino to depart, Markus Jensen to succeed
Innate also announced the appointment of Markus Jensen as chief medical officer and member of the executive leadership team, effective September 1, succeeding Sonia Quaratino. Jensen joined Innate Pha...
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have...
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that, subject to the closing of its ...
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi®) today...
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
MARSEILLE, France--(BUSINESS WIRE)-- #Cancer--Innate Pharma to participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference.
Innate Pharma completes enrollment in dose escalation of IPH4502 study
Innate Pharma (IPHA) announced the completion of enrollment in the dose escalation of the Phase 1 study of IPH4502, its proprietary Nectin-4 exatecan ADC. Preliminary data are expected by year-end…
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced the completion of enrollment in the dose escalation of the Phase 1 study of IPH4502 (NCT06781983), its...
Innate Pharma Slides: Corporate presentation
Innate Pharma has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Outcome of Innate Pharma's 2026 Annual General Meeting
MARSEILLE, France--(BUSINESS WIRE)--Outcome of Innate Pharma's 2026 Annual General Meeting.
Innate Pharma to participate in the Jefferies Global Healthcare Conference
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to Participate in the Jefferies Global Healthcare Conference.
Innate Pharma Q1 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 ...